Visit us at booth #111 and join our co-presentation with Moderna at the World Vaccine & Immunotherapy Congress.

Mapping Human Immunity

Mapping Human Immunity

Serimmune is an immune intelligence company that decodes the breadth and complexity of human antibody response, empowering discovery projects through a universal serology assay that identifies disease-specific epitopes across proteins and entire proteomes.

Serimmune Inc. is a Phase 1 winner in the LYMEX Diagnostic Prize

What We Do

We offer a discovery service to academia, government and industry through the Serimmune universal serology platform that utilizes bacterial display peptide library technology and next generation sequencing to broadly profile antibody repertoires and identify antigens and epitopes associated with many diseases - all in a single assay.

Services

How We Do It

Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next-generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity. Through this, we gain a broad view of an individual’s environmental exposures and the unique immune responses to these exposures in disease and health.

Technology

Why We Do It

Serimmune was founded on the belief that the information coded in the individual’s functional antibody repertoire is key to understanding human disease. To fulfill this vision, we created a technology for building and interpreting a dynamic map of human immunity which continually evolves to map interactions between functional antibody repertoire and human disease. Linkages between antibody response to pathogens have been shown in oncology, autoimmune, infectious, neurodegenerative, and other complex diseases.

About Us

Immuno-Therapeutics

Vaccines

Target Discovery

Serimmune Discovery Service

Learn about Serimmune’s SERA platform which combines large biological libraries, NGS, and custom bioinformatics to unlock the Circulating Antibody Repertoire to achieve hypothesis free serology.

Neutralizing Epitopes

Biomarkers of Response

Events

World Vaccine & Immunotherapy Congress: West Coast 2022


Nov 29th - Dec 1st

Visit us at booth #111 and join our co-presentation with Moderna at the Immune Profiling and Vaccine Technology track, on day 2 of the main congress – November 30th where we will be discussing how SERA Identifies Antibody Epitopes Induced by Moderna Vaccines and Boosters.

Register

Contact Us







    Academic and Government Collaborators